ClinicalTrials.gg
CompletedNCT02941848Updated Oct 21, 2016

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

A Phase 1 interventional study of HGP0816 and HGP1404 in Primary Hypercholesterolemia, sponsored by Hanmi Pharmaceutical Company Limited. Completed. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate Pharmacokinetic Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in the healthy adults.

Read the detailed description

A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in the healthy adults

02

Conditions studied

  • Primary Hypercholesterolemia
03

In context

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 60 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

[Inclusion criteria]

  1. Healthy adult of 19 to 50 of age at screening.
  2. 18.5 ≤ (BMI) \< 25.

    ※ BMS (kg/m2)= body weight (kg)/[height (m)2]

  3. Body weight ≥ 55 kg for men and ≥ 50 kg for women.
  4. Individual considered by the responsible physician to be eligible as a subject based on the results of hematology test, blood chemistry test, immunoserology test, urinalysis, and (ECG) as performed according to the characteristics of the drug (including those with not (NCS) abnormalities).
  5. Women must have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and a negative pre-dose urine β-hCG test at a time point defined in the protocol and must be applicable to one of the followings.

    • (no spontaneous menstruation for at least 2 years)
    • Surgical sterilization (sterilized by hysterectomy, bilateral ovariectomy or tubal ligation, or other methods)
    • A male partner is sterilized prior to screening (documented azoospermia following vasectomy) and this man is the subject's only partner.
    • The subject must agree to use adequate methods of continuously and properly during the period of time from at least 14 days prior to the first dose to at least 28 days after the last dose of the product.

      • Adequate methods of contraception include abstinence and physical barrier methods (e.g., condom, diaphragm, or cervical cap) and contraceptive devices or pills containing hormones that may have drug-drug interactions with the investigational product are not to be used during the study period, in principle.
  6. Sexually active male subject with a female partner of must agree to avoid pregnancy (condom, etc.) during the study and to maintain adequate methods of contraception and not donate sperms during the study and for 28 days after the last dose of the investigational product (the methods of contraception are not necessary if the male subject or his female partner is sterile).
  7. After receiving and understanding sufficient explanations about the study, the individual must voluntarily decide to participate in the study and provide written to complying with study instructions.

[Exclusion criteria]

  1. Evidence or history of clinically significant diseases in the hepatobiliary system, kidney, nervous system, psychiatric system, respiratory system, endocrine system (thyroid dysfunction, etc.), hemato-oncology, cardiovascular system, immune system, or musculoskeletal system (myopathy, etc.).
  2. History of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis) or surgery (except for simple typhlotomy or hernia repair) that may affect the absorption of the investigational product.
  3. reactions to any of the components of the investigational product or its or drugs of the same class.
  4. Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  5. Vital signs measured in the sitting position after at least 5 minutes of rest as follows: systolic blood pressure (SBP) > 150 mmHg or \< 90 mmHg or diastolic blood pressure (DBP) > 100 mmHg or \< 50 mmHg.
  6. Screening clinical laboratory test results as follows:

    • Blood total level > 1.5 x (ULN)
    • Blood (AST, also known as serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT, also known as serum glutamate pyruvate transaminase [SGPT]) > 1.25 x ULN
    • Blood urea nitrogen (BUN) > 25.0 mg/dL or creatinine > 1.4 mg/dL
    • Estimated (eGFR) \< 60 mL/min/1.73m2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation

      ※ eGFR (mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age (years)]-0.203 (X 0.742, if female)

    • Blood Creatinine Phosphokinase (CK) > 2 x ULN
  7. History of significant drug abuse within 1 year of screening or positive urine drug test results.
  8. Administration of drugs within 30 days of the investigational product administration that are expected to or may affect the metabolism of the investigational product.
  9. Administration of the following drugs within the relevant period, except for local agents without significant systemic absorption and hormonal contraceptives.

    • Ethical (ETC) drugs within 14 days of the first investigational product administration
    • Over-the-counter (OTC) drugs including health foods and vitamin preparations within 7 days of the first investigational product administration
    • Drugs administered via depot injection or other implantations (except for contraceptives) within 30 days of the first investigational product administration
  10. Significant alcohol dependency within 1 year of screening, continuous drinking within 6 months of screening (> 210 g/week), or unable to refrain from drinking during the study period starting from 2 days prior to the first investigational product administration.
  11. Continuous caffeine intake (e.g., coffee > 5 cups/day, tea > 1250 cc/day, cola > 1250 cc/day) or unable to refrain from caffeine intake during the study period starting from 2 days prior to the first investigational product administration.
  12. Continuous smoking (> 10 cigarettes/day) or unable to refrain from smoking during the study period starting from 2 days prior to the first investigational product administration.
  13. Intake of grapefruits or foods containing grapefruits within 7 days prior to the first investigational product administration.
  14. Participation in another clinical trial (including a bioequivalence study) and administration of another investigational product within 60 days prior to the investigational product administration in this study (3 months for biologics; a prolonged period of time may be applied with half life taken into account).
  15. Whole blood donation within 60 days or apheresis donation within 30 days prior to the investigational product administration.
  16. Pregnant or lactating women.
  17. Subject considered by the investigator to be inappropriate for study participation due to other reasons.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group1

    C → A + B A : HGP0816 B : HGP1404 C : HCP1306

    Drug: HGP0816 · Drug: HGP1404 · Drug: HCP1306

  • Experimental
    Group2

    A + B → C A : HGP0816 B : HGP1404 C : HCP1306

    Drug: HGP0816 · Drug: HGP1404 · Drug: HCP1306

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  2. Cmax of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  3. AUClast of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  4. Cmax of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

Secondary outcomes

  1. AUCinf of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  2. tmax of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  3. t1/2 of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  4. CL/F of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  5. Vd/F of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  6. MRT of Rosuvastatin

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  7. AUCinf of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  8. Tmax of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  9. T1/2 of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  10. CL/F of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  11. Vd/F of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

  12. MRT of Free Ezetimibe

    Time frame: Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Min KL, Park MS, Jung J, Chang MJ, Kim CO. Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clin Ther. 2017 Sep;39(9):1799-1810. doi: 10.1016/j.clinthera.2017.07.038. Epub 2017 Aug 10. PubMed 28803122 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2016
First posted
Oct 21, 2016
Start
Nov 2014
Primary completionActual
Dec 2014
CompletionActual
Jan 2015
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02941848
Responsible party
Sponsor
First posted
Oct 21, 2016
Start date
Nov 2014
Primary completion
Dec 2014
Completion
Jan 2015
Last update
Oct 21, 2016

Study contacts

Choon Ok Kim, MD
principal investigator · Yonsei University Health System, Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HGP0816 · HCP1306

Start the discussion